Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling

Greater use of small molecule biomarkers in drug development is needed to transform efficiency and success rates, by driving deeper understanding of how non-genetic factors influence disease pathobiology and drug responsiveness.

In this session, Sapient will discuss how its next-generation rapid liquid chromatography-mass spectrometry systems enable untargeted small molecule biomarker discovery at unprecedented speed and at population scale, with the ability to assay >11,000 circulating factors per biosample in <1 minute per sample run.

During this talk we discuss:

• How Sapient systems enable a new scale of biomarker discovery
• 4D chemical characterization of known and unknown molecules
• Rapid biomarker cross-validation